Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
01:36pm, Wednesday, 27'th May 2026
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF modeling. CRMD faces a 2027 revenue trough post-TDAPA, but I expect growth to reignite from 2027 to
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
06:05am, Friday, 22'nd May 2026
CorMedix NASDAQ: CRMD CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
11:16am, Friday, 15'th May 2026
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
08:30am, Friday, 15'th May 2026
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Ca
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
01:54pm, Thursday, 14'th May 2026
CorMedix Therapeutics Inc. (NASDAQ:CRMD) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting strong first-quarter results driven by higher utilization of DefenCath and contr
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
12:40pm, Thursday, 14'th May 2026
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Q1 Earnings Call Highlights
10:09am, Thursday, 14'th May 2026
CorMedix NASDAQ: CRMD reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while manageme
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
09:46am, Thursday, 14'th May 2026
CorMedix (CRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.3 per share a year ago.
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
07:30am, Thursday, 14'th May 2026
‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ C
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:00am, Thursday, 07'th May 2026
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
08:30am, Tuesday, 05'th May 2026
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study
01:00pm, Monday, 27'th Apr 2026
CorMedix Inc. (NASDAQ:CRMD) shares are up on Monday following the announcement of positive topline results from the Phase 3 ReSPECT trial assessing REZZAYO (rezafungin) for the prophylaxis of invasive
– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –
CorMedix: A Shrinking Core And No Proven Second Engine
03:02am, Wednesday, 08'th Apr 2026
CorMedix is entering a post-TDAPA reset, with DefenCath revenue expected to decline materially and no proven second growth engine in place. FY26 guidance of ~$310M (midpoint) masks underlying decelera
CorMedix to Participate in Needham Virtual Healthcare Conference
08:30am, Tuesday, 07'th Apr 2026
PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threateni
